• Moderna published Phase 3 results for its mRNA-1010 flu vaccine in the New England Journal of Medicine.
• The mRNA flu vaccine showed higher efficacy compared with standard seasonal flu shots.
• Regulatory filings are in progress in the US, EU, and other regions to seek approval for mRNA-1010.

For investors watching NasdaqGS:MRNA, this flu update comes with the stock at $48.79 and a mixed return profile. The share price is up 6.7% over the past week, flat over 30 days, and higher by 58.1% year to date and 102.8% over 1 year, while longer 3 and 5 year periods show large declines. That backdrop helps frame how new product milestones might affect sentiment around Moderna beyond its earlier COVID-19 focus.

The mRNA-1010 data and ongoing filings point to a clearer path for Moderna to participate in the broader respiratory vaccine market. As regulators review the application in the US, EU, and elsewhere, investors can watch how this potential flu franchise fits into Moderna's pipeline and how the company communicates its next steps on manufacturing, commercial plans, and additional late stage programs.

Stay updated on the most important news stories for Moderna by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Moderna.

Quick Assessment

• ⚖️ Price vs Analyst Target: At $48.79, Moderna trades about 12.5% above the US$43.37 analyst target, slightly ahead of consensus but still within the published US$21 to US$69 range.
• ✅ Simply Wall St Valuation: Simply Wall St estimates the stock is trading 51.7% below its fair value, flagging it as undervalued on that model.
• ⚖️ Recent Momentum: The 30 day return is roughly flat at 0.04%, so the flu data is landing without a strong short term trend in either direction.

There is only one way to know the right time to buy, sell or hold Moderna. Head to Simply Wall St's company report for the latest analysis of Moderna's Fair Value.

Key Considerations

• 📊 Strong Phase 3 flu results and ongoing filings broaden Moderna's story beyond COVID-19, which could matter for how investors view long term revenue mix.
• 📊 Keep an eye on regulatory timelines, pricing versus existing flu vaccines, and any early guidance on expected uptake once approvals are in place.
• ⚠️ Even with no flagged company specific risks here, approval delays, competitive mRNA flu programs, or safety signals could change the risk reward balance quickly.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Moderna analysis. Alternatively, you can visit the community page for Moderna to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.